Compugen Stock

Compugen EV/Revenue

The EV/Revenue (Enterprise Value to Revenue) of Compugen (CGEN) as of Aug 8, 2026 is 0.74. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 3.45 — a change of -78.57% (lower).

EV/Revenue

0.74

YoY

-78.57%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of Compugen is 2026 0.74 . EV/Revenue (Enterprise Value to Revenue) of Compugen was 2025 3.45 . It decreases by -78.57% lower compared to the previous year.
Access this data via the Eulerpool API

Compugen Stock analysis

What does Compugen do? Compugen Ltd is an Israeli biotechnology company focused on the development of therapeutics and diagnostic products. It was founded in 1993 and is headquartered in Tel Aviv. Compugen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Compugen stock

EV/Revenue (Enterprise Value to Revenue) of Compugen is 0.74 in 2026.

EV/Revenue (Enterprise Value to Revenue) of Compugen changed from 3.45 to 0.74, representing a -78.57% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) Compugen since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s Compugen with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Compugen

All Key Metrics — Compugen